- Home
- DTIL vs MAIA Comparison
DTIL vs MAIA Comparison
Compare DTIL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- MAIA
- Stock Information
- Founded
- DTIL 2006
- MAIA 2018
- Country
- DTIL United States
- MAIA United States
- Employees
- DTIL N/A
- MAIA N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- MAIA Health Care
- Exchange
- DTIL Nasdaq
- MAIA Nasdaq
- Market Cap
- DTIL 43.3M
- MAIA 44.8M
- IPO Year
- DTIL 2019
- MAIA 2022
- Fundamental
- Price
- DTIL $4.49
- MAIA $1.48
- Analyst Decision
- DTIL Strong Buy
- MAIA
- Analyst Count
- DTIL 3
- MAIA 0
- Target Price
- DTIL $37.67
- MAIA N/A
- AVG Volume (30 Days)
- DTIL 134.4K
- MAIA 124.0K
- Earning Date
- DTIL 03-26-2025
- MAIA 05-13-2025
- Dividend Yield
- DTIL N/A
- MAIA N/A
- EPS Growth
- DTIL N/A
- MAIA N/A
- EPS
- DTIL 1.04
- MAIA N/A
- Revenue
- DTIL $68,696,000.00
- MAIA N/A
- Revenue This Year
- DTIL N/A
- MAIA N/A
- Revenue Next Year
- DTIL $58.46
- MAIA N/A
- P/E Ratio
- DTIL $4.32
- MAIA N/A
- Revenue Growth
- DTIL 40.98
- MAIA N/A
- 52 Week Low
- DTIL $3.61
- MAIA $1.46
- 52 Week High
- DTIL $15.97
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- DTIL 38.26
- MAIA 35.67
- Support Level
- DTIL $4.25
- MAIA $1.52
- Resistance Level
- DTIL $5.72
- MAIA $1.95
- Average True Range (ATR)
- DTIL 0.38
- MAIA 0.11
- MACD
- DTIL -0.07
- MAIA -0.01
- Stochastic Oscillator
- DTIL 16.33
- MAIA 5.09
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.